Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences)
Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer
The CRC Digest